Hebrew University researchers have recently developed a bio-electronic sensor for the detection of chemicals such as nerve gases and insecticides by irreversible inhibition of the enzyme acetylcholine esterase.
The Israeli start-up company, Nanolymf Ltd, believes its technology has the potential to allow the oral administration of some of the biggest intravenous and injectable drugs on today’s market.
Instead of asking friends "How do you feel?" or doctors examining patients, one day such queries and examinations may be replaced by tiny radio antennas implanted under the skin to act as remote sensors of humans' emotional, physiological state. Scientists at the Hebrew University's applied physics department have discovered a method for remote sensing of people's physiological and emotional state.
Recent research conducted by Dr. Hermona Soreq and co-workers at the
Alexander Silberman Life Sciences Institute at The Hebrew University of
Jerusalem, in collaboration with PharmAthene, examined the role of rBChE in
the prevention of amyloid plaques, which are believed to play a role in the
development of Alzheimer's disease.
The innovative cationic emulsion for the treatment of dry eye symptoms is the first product developed from its pipeline to be marketed
Yissum Technology Transfer Company of the Hebrew University of Jerusalem ended 2007 with $51 million revenue, 27% more than in 2006.
The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.
Nava Swersky Sofer congratulating Israel on it's 60th anniversary on a special Forbes edition.
The unique case-controlled DNA database for genetic association studies will allow the scientific community to access DNA samples directly via the Internet (www.hugr.org) and test genes of interest.
The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews
Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.
Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).
Globes article portraying Israeli Technology Transfer (Hebrew)
The Acetylcholinesterase (AChE) Program is being conducted
under the agreement the Company entered into with Yissum Research and
Development Company, the technology transfer arm of the Hebrew University of
Jerusalem, Israel, and the Boyce Thompson Institute, Inc.
Israel 21c portraying Nava Swersky Sofer, Yissum's President & CEO
The FDA approved the trial at 5 Israeli hospitals and one in Arizona.
Yissum and Eucalyptus Biosciences Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases
Israel's Universities and institutes are all about developing and selling technology
Jerusalem-based Yissum has formed a spin-off company - Nanolymf, which will
be dedicated to advancing a nanotechnology controlled-release drug delivery platform.